enGene Holdings Inc. Common Stock earnings per share and revenue
On Dec 22, 2025, ENGN reported earnings of -0.73 USD per share (EPS) for Q4 25, missing the estimate of -0.57 USD, resulting in a -25.95% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.13% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of -0.56 USD, with revenue projected to reach -- USD, implying an decrease of -23.29% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were enGene Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, enGene Holdings Inc. Common Stock reported EPS of -$0.73, missing estimates by -25.95%, and revenue of $0.00, 0% as expectations.
How did the market react to enGene Holdings Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 5.13%, changed from $8.77 before the earnings release to $9.22 the day after.
When is enGene Holdings Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 02, 2026.
What are the forecasts for enGene Holdings Inc. Common Stock's next earnings report?
Based on 11
analysts, enGene Holdings Inc. Common Stock is expected to report EPS of -$0.56 and revenue of -- for Q1 2026.